Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1

Conditions

Select Advanced Solid Tumors 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 125pembrolizumab 123Magnetic Resonance Spectroscopy 108Carboplatin 89Cyclophosphamide 80Biopsy 69Cisplatin 67Paclitaxel 61Bevacizumab 56Gemcitabine 54Nivolumab 49fludarabine 48Dexamethasone 41Rituximab 39Pemetrexed 39Fluorouracil 39Radiotherapy 37Doxorubicin 37atezolizumab 36Docetaxel 36Leucovorin 35Oxaliplatin 32Capecitabine 32venetoclax 31Temozolomide 29Prednisone 29durvalumab 27Standard of Care 27Radiation 27Letrozole 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Interleukin-2 × 30 days × Clear all
NCT06598371 2026-05-20

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
141 enrolled
Other solid neoplasm

Select Advanced Solid Tumors

NCT07591649 2026-05-19

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

Masonic Cancer Center, University of Minnesota

Phase 1/2 Recruiting
18 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡